Evidence map›Paper›PMID 42421168›Full record

ArticleAdvanced healthcare materials2026

Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis.

Vanessa Chan, Po-Han Chao, XuXin Sun, Jun Han, Sarah MacPherson, Lucas J Andrew, Noah Y Brittain, Tien Do, Marcel B Bally, Julian J Lum and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vanessa ChanFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Po-Han ChaoFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
XuXin SunBasic and Translational Research Department, BC Cancer Research Institute, Vancouver, British Columbia, Canada.
Jun HanDivision of Medical Sciences, Genome British Columbia Proteomics Centre, University of Victoria, Victoria, British Columbia, Canada.
Sarah MacPhersonTrev and Joyce Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
Lucas J AndrewFaculty of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
Noah Y BrittainFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Tien DoFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Marcel B BallyFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Julian J LumTrev and Joyce Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.ORCID https://orcid.org/0000-0002-5624-3541
Shyh-Dar LiFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0002-1763-2667

Funding

Canadian Cancer Society 706231CIHR PJT-168861Nanomedicine Innovation Network 2020-T1-02National Organization for Rare Disorders - Appendix Cancer/Pseudomyxoma Peritonei Research Foundation 18004Natural Science and Engineering Research Council in Canada RGPIN-2023-04020
6 · The paper itself

Abstract

Peritoneal carcinomatosis (PC) is an aggressive manifestation of advanced gynecological and gastrointestinal malignancies with high recurrence rates despite cytoreductive surgery and chemotherapy. We developed a cationic liposomal nanoparticle (DSTAP, ∼159 nm) to deliver and retain the toll-like receptor 7/8 agonist Resiquimod (R848) within the peritoneal cavity, aiming to modulate the tumor immune microenvironment (TIME) and improve therapeutic efficacy. DSTAP-R848 was evaluated in murine colorectal and ovarian PC models, alone or combined with oxaliplatin (Oxa). Survival, cure rates, and durable immunity following tumor rechallenge were assessed. Immune polarization was examined by incubating ascites and peritoneal fluid with naïve splenocytes, while flow cytometry and metabolomic profiling characterized intratumoral immune populations and metabolic changes. Combination therapy achieved cure rates of 80% in the colorectal model and 30% in the ovarian model, with no recurrence after rechallenge; Oxa monotherapy yielded no cures. Oxa+DSTAP-R848 increased CD8

Indexed as

Antineoplastic AgentsImidazolesNanoparticlesPeritoneal NeoplasmsAnimalsCell Line, TumorFemaleMiceMice, Inbred C57BLOvarian NeoplasmsOxaliplatinToll-Like Receptor AgonistsTumor MicroenvironmentAntineoplastic AgentsImidazolesOxaliplatinresiquimodToll-Like Receptor Agonistscancer immunotherapycolorectal cancermetabolomicsnanomedicineovarian cancerperitoneal carcinomatosistumor immune microenvironment

Identifiers

PMID42421168

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.